ARA-290 (Cibinetide) — Research Peptide Bulk Supply

• Lyophilized powder
• Purity: >99% by HPLC
• Available research vial sizes: 5 mg, 10 mg, 16 mg
• Storage: -20°C, protected from light; short-term 4°C acceptable
• Solubility: Soluble in water or 0.1% BSA-PBS
• COA with HPLC and mass spectrometry data provided per lot
• Cold-chain shipping documentation available
• Private-label and white-label bulk inquiry form available

ARA-290 is an 11-amino-acid synthetic peptide derived from the helix-B surface region of erythropoietin (EPO), engineered to selectively activate the innate repair receptor (IRR)—a heterodimer of EPOR and CD131—without binding the classical hematopoietic EPO receptor. In preclinical and Phase II clinical studies, activation of the IRR suppressed pro-inflammatory cytokines (TNF-α, IL-1β, IL-6) and NF-κB signaling while promoting neural cell survival and small-fiber nerve regeneration. A Phase II trial in sarcoidosis-associated small-fiber neuropathy reported improvements in corneal nerve fiber density and neuropathic symptom scores alongside reductions in HbA1c and lipid profiles without changes in hematocrit (https://pubmed.ncbi.nlm.nih.gov/23456859/). The peptide's anti-apoptotic properties extend to pancreatic islet cell models, where ARA-290 was observed to protect islets from cytokine-induced apoptosis and reduce macrophage secretion of IL-6, IL-12, and TNF-α (https://biotechpeptides.com/2023/02/24/research-applications-of-the-ara-290-peptide/).

For Research Use Only. Not for human or veterinary use. Page copy reflects published preclinical and biochemistry literature only and does not constitute dosage, administration, treatment, or therapeutic guidance.

• https://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?sid=348353636
• https://pubmed.ncbi.nlm.nih.gov/23456859/
• https://biotechpeptides.com/product/ara-290-16mg/
• https://www.corepeptides.com/peptides/ara-290-16mg/
• https://pmc.ncbi.nlm.nih.gov/articles/PMC7428518/